Credit Suisse analyst Dan Leonard raised the firm’s price target on Certara to $27 from $22 to reflect the strengthening role of biosimulation in both clinical and pre-clinical research and Certara’s leading market position. The firm keeps an Outperform rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERT:
- Exponent Set to Join S&P MidCap 400; CVR Energy and Certara to Join S&P SmallCap 600
- Certara adds deep learning capabilities to D360
- Certara announces release of Simcyp PBPK Simulator Version 22
- Certara price target raised to $21 from $20 at Barclays
- Certara CFO Andrew Schemick to transition to new role, John Gallagher to succeed
